



Asante Laboratory Services

2026 Gram-Negative Antibigram
(Statistics are calculated from 2025 susceptibility data)

Gram Negative Organisms (% represented)	Total # Isolates	Ampicillin ¹	Ampicillin/ Sulbactam ¹	Piperacillin/ Tazobactam ¹	Ertapenem	Meropenem	Aztreonam	Ciprofloxacin	Levofloxacin ⁷	Cefazolin (Urine) ⁵	Ceftazidime ¹	Ceftriaxone ¹	Cefepime	Cefepime SDD	Gentamicin	Trimeth/Sulfa	Nitrofurantoin ³
<i>Acinetobacter baumannii</i>	34		97	91		100		100			94	7	97		94	88	
<i>Citrobacter braakii</i>	68			89	97	100	89	85			88	87	99		92	91	90
<i>Citrobacter freundii</i> ²	82			90	100	100	92	90			91	91	100		93	85	91
<i>Citrobacter freundii</i> complex (46%)	49			92	100	100	88	82			92	89	100		100	92	86
<i>Citrobacter freundii</i> complex MDR ² (54%)	58			46	95	100	14	81			33	29	95	5	100	86	86
<i>Citrobacter koseri</i> ²	94			91	100	100	99	99			99	99	100		100	99	73
<i>Klebsiella aerogenes</i> ² (79%)	149			94	99	100	97	97	100		97	96	100		100	99	6
<i>Klebsiella aerogenes</i> MDR ² (21%)	39			10	89	97	19	87	83		13	10	95		97	97	10
<i>Enterobacter cloacae</i> complex ² (75%)	285			98	100	100	100	98	100		98	97	100		99	95	27
<i>Enterobacter cloacae</i> complex MDR ² (25%)	94			15	67	99	16	83			15	3	65	17	95	83	34
<i>Escherichia coli</i> (94%)	6204	68	76	97	100	100	100	88	92	97	99	99	100		95	85	97
<i>Escherichia coli</i> MDR (6%)	380	1	40	89	100	100	40	26	45	1	49	6	34	28	80	49	93
<i>Klebsiella oxytoca</i> (93%)	336		78	98	100	100	99	97	99		99	99	100		100	95	83
<i>Klebsiella oxytoca</i> MDR (7%)	24		0	23	100	100	19	54	99		75	0	42	42	46	38	75
<i>Klebsiella pneumoniae</i> (92%)	1142		92	95	100	100	100	97		99	100	100	100		100	96	27
<i>Klebsiella pneumoniae</i> MDR (8%)	95		20	55	98	99	11	27		1	36	6	20	31	76	19	7
<i>Morganella morganii</i> ²	93		14	100	100	100	100	88			99	100	100		92	88	
<i>Proteus mirabilis</i>	582	87	95	100	99	100	99	88	90	95	100	99	99		95	83	
<i>Proteus vulgaris</i>	32		77	100	100	100	100	100			100	100	100		100	97	
<i>Providencia rettgeri</i>	57		75	96	95	100	100	96			100	100	100		100	98	
<i>Pseudomonas aeruginosa</i> (96%)	788			95		98	*	89	95		97		98				
<i>Pseudomonas aeruginosa</i> MDR (4%)	36			50		36	*	42			44		58				
<i>Serratia marcescens</i>	110			100	100	100	99	98			99	100	99		100	100	
<i>Stenotrophomonas maltophilia</i>	102								95		40					99	

Additional antimicrobial data available. Blank spaces indicate that an antibiotic is either inappropriate or has not been tested for that organism.

**This antimicrobial may be appropriate for use in the treatment of infections caused by this organism. Antibigram data is not available due to limitations in our routine test system.

Disclaimer: Data provided for organism groups in red are under threshold (30) and may not be precise. These have been included for comparison to their counterpart non-MDR group.

FOOTNOTES:

- These antibiotics may be degraded by Inducible Beta Lactamases (IB).
- These organisms may produce Inducible Beta lactamases (IB).
- Nitrofurantoin used for uncomplicated UTI and for patients with GFR >60 only.
- Includes data from Asante Rogue Regional Medical Center, Asante Three Rivers Medical Center, and Asante Ashland Community Hospital.
- Urine Cefazolin results predict results for the oral agents cefaclor, cefdinir, cefpodoxime, cefuroxime axetil and cephalexin when used for therapy of uncomplicated UTIs due to *E. coli*, *K. pneumoniae* and *P. mirabilis*. Non-urine *E. coli*, *Klebsiella*, and *Proteus* spp. vs Cefazolin. Individual isolates may be tested using a disc diffusion method on request
- Organisms with n<30 excluded from Levofloxacin interpretations.



Asante Laboratory Services

2026 Gram-Positive Antibigram

(Statistics are calculated from 2025 susceptibility data)

Gram Positive Organisms (% represented)	Total # Isolates	Ampicillin	Penicillin	Penicillin (Oral) ¹	Penicillin (Parenteral) ¹	Penicillin (Meningitis) ¹	Oxacillin	Levofloxacin ⁵	Ceftriaxone	Ceftriaxone (Meningitis) ¹	Clindamycin	Erythromycin ³	Tetracycline ^{5,6}	Vancomycin	Daptomycin	Gentamicin Synergy	Streptomycin Synergy	Trimeth/Sulfa	Rifampin ⁷	Nitrofurantoin ⁴	Linezolid
Enterococcus faecalis	1221	100						91					29	100	100	85	93			99	97
Enterococcus faecium (67%)	74	74						55					67	96	**	96	82			22	97
Enterococcus faecium VRE (33%)	37	0						0					32	0	**	100	19			19	97
Staphylococcus aureus (MSSA) ² (63%)	1812						100	85			83	66	88	100	100			89	100	100	100
Staphylococcus aureus (MRSA) ² (37%)	1068						0	36			82	11	61	100	100			93	100	100	100
Staphylococcus epidermidis ²	165						40	74			62	36	80	100	100			57	100	100	100
Staphylococcus lugdunensis ²	217						86	99			86	84	94	100	100			99	100	100	100
Streptococcus agalactiae (Group B)	93		100					100	100			34		100							
Streptococcus pyogenes (Group A)	57		100					98	100			56		100							
Streptococcus anginosus	27		100					88	100			54		100							
Streptococcus pneumoniae ¹	117			83	99	83		97	99	96		75		100							
Streptococcus mitis/oralis	27		81					100	96					100							

Blank spaces indicate that an antibiotic is either inappropriate or has not been tested for that organism.

**This antimicrobial may be appropriate for use in the treatment of infections caused by this organism. Antibigram data is not available due to limitations in our routine test system.

FOOTNOTES:

1. Interpretations of Streptococcus pneumoniae susceptibility vary according to site of isolation (Penicillin and Ceftriaxone for CSF and non-CSF) and route of administration of some antimicrobials (Penicillin administered orally or parenterally). These interpretations are based on achievable blood and CSF levels for those antimicrobials.
2. Oxacillin resistance also implies resistance to cephalosporins, carbapenems, ticarcillin/clavulanic acid, ampicillin/sulbactam, and amoxicillin/clavulanic acid.
3. Azithromycin and Clarithromycin susceptibility may be deduced from Erythromycin results.
4. **Nitrofurantoin used for uncomplicated UTI and for patients with GFR >60 only.**
5. Levofloxacin and Tetracycline should only be used to treat Enterococci from uncomplicated UTIs
6. Isolates that test intermediate or resistant to Tetracycline should be tested against Doxycycline or Minocycline if those results are needed for treatment.
7. Rifampin should not be used alone for therapy.